Anti-STn Antibody

Description:

Dysregulation of cellular glycosylation is a common characteristic of many cancers (1). The STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), also known as the sialyl-Tn antigen, is up-regulated in a wide variety of cancers (2). It is formed from the Tn antigen (GalNAcα1-O-Ser/Thr) through the action of the ST6GalNAc family of enzymes (3,4). STn-Keyhole Limpet Hemocyanin conjugate has been tested as an anti-cancer vaccine (5). The specificity of the anti-STn monoclonal antibody was shown by binding to bovine submaxillary mucin (BSM), which presents the STn antigen, and not to asialo-BSM (ref 2 and Figure 1 panel B). This antibody was previously marketed under HB-STn (3,4).

Hakomori, S. (1996) Cancer Res. 56, 5309.

Kjeldsen, T. et al. (1988) Cancer Res. 48, 2214.

Marcos, N.T. et al. (2004) Cancer Res. 64, 7050.

Julian, S. et al. (2001) Glycocon. J. 18, 883.

Miles, D. et al. (2006) J. Biol. Chem. 281, 3586.

Preparation: Monoclonal antibodies were produced from the mouse hybridoma 3F1 clone (HB-STn).

Purification: This IgG1 was purified by Protein G affinity chromatography.